Nestle to buy Aimmune Therapeutics for $2.6 billion

A pedestrian passes a Nestle SA logo at the Nescafe factory, operated by Nestle SA, in Tutbury, U.K., on Thursday, Aug. 23, 2018.

Simon Dawson | Bloomberg | Getty Images

Nestle said it was offering $34.50 per share for the remaining 74.4% in peanut allergy treatment maker Aimmune Therapeutics it does not already own as it adds what it hopes will be a lucrative treatment to its portfolio.

The offer values the California-based biopharmaceutical company at $2.6 billion, including the $473 million that Nestle had already invested in Aimmune, Nestle said in a statement.

The price represents a 174% premium to Aimmune’s closing share price on August 28 of $12.60, said the food giant, which has been gearing its traditional portfolio towards health and wellness products.

Up to 240 million people worldwide suffer from food allergies, peanut allergy being the most common, Nestle said.

In January, Aimmune Therapeutics got approval from the U.S. Food and Drug Administration (FDA) for Palforzia, making it the first medication approved for food allergies in children and teens.

Nestle said the acquisition was expected to add to organic growth in 2021 and to cash earnings by 2022/23.

Source link




Serbia, Kosovo agree to normalize economic ties

U.S. President Donald Trump speaks during a meeting with Serbia's President Aleksandar Vucic and Kosovo's Prime Minister Avdullah Hoti at the White House...

Dyson V10 Animal Cordless Stick Vacuum

Powerful suction to deep clean everywhereEngineered for whole-home, deep cleaningSuction power, run time and tools designed to deep clean your whole home.Dyson technology...

Biden leads Trump after debate, coronavirus diagnosis

Former Vice President Joe Biden leads President Donald Trump in six swing states after the first 2020 presidential debate and following the president's...

Company wants people to understand shoes’ carbon footprint

LONDON — When Allbirds founders Tim Brown and Joey Zwillinger launched the footwear brand in 2016, they wanted to make a simple-looking shoe...